Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3126-3135

  Burns, Jorge S ^a   Abdallah, Basem M ^a   Guldberg, Per ^b   Rygaard, Jørgen ^c   Schrøder, Henrik D ^a   Kassem, Moustapha ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c Kommunehospitalet ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ARF PROTEIN; COLECALCIFEROL; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; OSTEOCALCIN; PROCOLLAGEN; PROTEIN P16INK4A; TELOMERASE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL POPULATION; CONTACT INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EXTRACELLULAR MATRIX; GENE DELETION; GENE LOCUS; GENE SILENCING; GENETIC EPIGENESIS; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IN VIVO CULTURE; LATENT PERIOD; LONG TERM EXPOSURE; MESENCHYME; MICROENVIRONMENT; MOLECULAR CLONING; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 17144384449     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2218     Document Type: Article

References (70)

1. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
2. Simonsen JL, Rosada C, Serakinci N, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592-6.
3. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919-26.
4. Shi S, Gronthos S, Chen S, et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 2002;20:587-91.
5. Xu J, Yang X. Telomerase activity in early bovine embryos derived from parthenogenetic activation and nuclear transfer. Biol Reprod 2001;64:770-4.
6. Jiang XR, Jimenez G, Chang E, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 1999;21:111-4.
7. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999;21:115-8.
8. Wang J, Hannon GJ, Beach DH. Risky immortalization by telomerase. Nature 2000;405:755-6.
9. Farwell DG, Shera KA, Koop JI, et al. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol 2000;156:1537-47.
10. Lindvall C, Hou M, Komurasaki T, et al. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003;63:1743-7.
11. Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR. Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene 2004;23:3116-21.
12. Mondello C, Chiesa M, Refauzzini P, et al. Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals. Biochem Biophys Res Commun 2003;308:914-21.
13. Milyavsky M, Shats I, Erez N, et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res 2003;63:7147-57.
14. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere lengthindependent mechanism. Proc Nad Acad Sci U S A 2002;99:12606-11.
15. Chang S, DePinho RA. Telomerase extracurricular activities. Proc Natl Acad Sci U S A 2002;99:12520-2.
16. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003;5:474-9.
17. Serakinci N, Guldberg P, Burns JS, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004;23:5095-8.
18. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-57.
19. Madsen MW, Moyret C, Theillet C, Briand P. Growth factor requirement, oncogene expression and TP53 mutations of a tumorigenic and a non-tumorigenic subline of the human breast carcinoma cell line, HMT-3909. Eur J Cancer 1995;31A:362-7.
20. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. Science 1997;276:1425-8.
21. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
22. Yamada KM. Cell biology: tumour jailbreak. Nature 2003;424:889-90.
23. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;11433-45.
24. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94:569-74.
25. Hedlund TE, Duke RC, Miller GJ. Three-dimensional spheroid cultures of human prostate cancer cell lines. Prostate 1999;41:154-65.
26. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974;33:1027-33.
27. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 2002; 273:21-33.
28. Wege H, Chui MS, Le HT, Tran JM, Zern MA. SYBR Green real-time Telomeric Repeat Amplification Protocol for the rapid quantification of telomerase activity. Nucleic Acids Res 2003;31:E3.
29. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
30. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997;9:348-55.
31. INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000;14:1727-35.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
33. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
34. Gao S, Worm J, Guldberg P, et al. Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. Br J Cancer 2004;91:760-4.
35. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 2004;19:841-52.
36. Zhu GG, Stenback F, Risteli L, Risteli J, Kauppila A. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study. Cancer 1993;72:1679-84.
37. Cheuk W, Wong KO, Wong CS, Chan JK. Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am J Surg Pathol 2004;28:801-7.
38. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kipl) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94:6380-5.
39. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-46.
40. Cotsiki M, Lock RL, Cheng Y, et al. Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bubl. Proc Natl Acad Sci U S A 2004;101:947-52.
41. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
42. Counter CM, Hahn WC, Wei W, et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 1998;95:14723-8.
43. Valera A, Perales JC, Hatzoglou M, Bosch F. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum Gene Ther 1994;5:449-56.
44. Sanchez-Carbayo M, Belbin TJ, Scotlandi K, et al. Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes. Lab Invest 2003;83:507-17.
45. Keith WN. From stem cells to cancer: balancing immortality and neoplasia. Oncogene 2004;23:5092-4.
46. Martin JA, Forest E, Block JA, et al. Malignant transformation in human chondrosarcoma cells supported by telomerase activation and tumor suppressor inactivation. Cell Growth Differ 2002;13:397-407.
47. Nishiyama H, Gill JH, Pitt E, Kennedy W, Knowles MA. Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 2001;20:2956-64.
48. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002;133:105-11.
49. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
50. Cobbers JM, Wolter M, Reifenberger J, et al. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998;8:263-76.
51. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8:1276-80.
52. Harley CB. Telomerase is not an oncogene. Oncogene 2002;21:494-502.
53. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-5.
54. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
55. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
56. 3, TGF-β, and dexamethasone reveals physiological regulation of alkaline phosphatase, dissociated osteocalcin gene expression, and protein synthesis and lack of mineralization. J Cell Biochem 2002;85:279-94.
57. Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000;20:1436-47.
58. Lian JB, Stein GS. Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Crit Rev Oral Biol Med 1992;3:269-305.
59. Marx J. Cancer research. Mutant stem cells may seed cancer. Science 2003;301:1308-10.
60. Ribatti D, Vacca A, Dammacco F. New non-angiogenesis dependent pathways for tumour growth. Eur J Cancer 2003;39:1835-41.
61. Tomlinson IP, Bodmer WF. Modelling the consequences of interactions between tumour cells. Br J Cancer 1997;75:157-60.
62. Chen CS, Toda K, Fujii K, Imamura S. Further characterization of a new in vitro angiogenesis model undei serum free culture conditions; suppression of endothelial cell differentiation by serum. J Dermatol Sci 1998;16:208-15.
63. Hart IR. Perspective: tumour spread - the problems of latency. J Pathol 1999;187:91-4.
64. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54.
65. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
66. Kauppila S, Bode MK, Stenback F, Risteli L, Risteli J. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo. Br J Cancer 1999;81:654-61.
67. Qing J, Maher VM, Tran H, Argraves WS, Dunstan RW, McCormick JJ. Suppression of anchorage-independent growth and Matrigel invasion and delayed tumor formation by elevated expression of fibulin-ID in human fibrosarcoma-derived cell lines. Oncogene 1997;15:2159-68.
68. Chatterjee SJ, George B, Goebell PJ, et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004;203:762-70.
69. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003;3:111-5.
70. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview. Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.